Robert Dillard

Robert Dillard is a contributing writer for GU Oncology Now and its parent company, Mashup Media, LLC. As a medical writer and editor, Mr. Dillard is experienced at producing high-quality clinical articles, blog articles, news releases, white papers, and educational and promotional content. Mr. Dillard has been writing in the health care space for more than 7 years and previously served as a public relations specialist. He received his BA in public relations from Rowan University.

Articles by Robert Dillard

Robert DillardPhenotypic Precision Medicine in Advanced Prostate Cancer | November 18, 2022
A polygenic hazard score (PHS290) is able to stratify US veterans of diverse ancestry for lifetime risk of prostate cancer.
Read More
A study assessed the link between benign prostatic hyperplasia (BPH) and prostate cancer (PCa).
A corrected genetic risk score (GRS) based on non-European racial/ethnic populations is more appropriate for genetic testing.
Genetic testing rates are low for prostate cancer.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 25, 2022
RGPT is reliable in terms of safety and short-term clinical outcomes in patients with prostate cancer.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 25, 2022
Researchers assessed the kinetics of PSMA PET uptake in prostate cancer lesions following radiation therapy.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 25, 2022
HDR brachytherapy as a salvage local therapy in prostate cancer has pros and cons.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 25, 2022
Researchers observed that patients with prostate cancer with high ATM have worse outcomes.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 24, 2022
A study compared the use of different radiation therapy (RT) techniques in prostate cancer.
Robert DillardASTRO 2022: Focus on Prostate Cancer | October 24, 2022
Dose-intensified radiation therapy does not yield increased survival in prostate cancer compared with today treatment.